EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Improved FAPI-radiopharmaceutical pharmacokinetics from the perspectives of a dose escalation study

Adrianna Bilinska, Sanjana Ballal, Chandrasekhar Bal, Tilman Läppchen, Eirinaios Pilatis, Elena Menéndez, Euy Sung Moon, Marcel Martin, Frank Rösch, Axel Rominger, Eleni Gourni iD

European Journal of Nuclear Medicine and Molecular Imaging · 2025

DOI: 10.1007/s00259-025-07141-1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2025. Verfasst von Adrianna Bilinska und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Inselspital, Bern University Hospital, Bern, Switzerland. Hauptthemen laut MEDLINE: Radiopharmaceuticals, Membrane Proteins, Gelatinases. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Bern.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

This study explores the use of fibroblast activation protein inhibitors (FAPI) targeting radiopharmaceuticals as a new approach for pan-cancer treatment, focusing on key factors affecting their effectiveness. We hypothesized that adjusting the administered radiotracer dose one could enhance the tumor-to-background ratios.

Methods

In a dose-escalation study with PC3 xenografts, all radiotracers were administered at doses between 10 and 1500 pmol, followed by biodistribution and PET/CT imaging. Their selectivity towards FAP, PREP, and DDP4, along with their stability in vivo, was assessed by biodistribution and metabolite analysis, respectively. Organ FAP expression was quantified using qPCR, and circulating FAP (sFAP) levels were measured in mouse and human blood samples via ELISA. Proof-of-principle human studies were also conducted.

Results

Increasing the dose from 10 to 600 pmol significantly reduced blood uptake and enhanced tumor uptake, optimizing their in vivo performance. All radiotracers showed peak efficacy at 350–600 pmol, with altered pharmacokinetics beyond 600 pmol. Biodistribution studies validated the in vivo selectivity of all radiotracers towards FAP, even in the presence of PREP and DPP4 inhibitors, while they demonstrated remarkable stability in vivo. FAP expression was confirmed in various organs, with sFAP quantified in both healthy mice and humans. Human studies with [ 68 Ga]Ga-DOTA.SA.FAPI revealed reduced off-target uptake (e.g., pancreas, salivary glands, heart), aligning with the preclinical findings.

Conclusion

The study highlights the crucial need for precise FAPI-radiotracer dosing, optimizing PET imaging, reducing radiation exposure, and enhancing treatment by accounting for FAP biology and sFAP’s influence on pharmacokinetics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RadiopharmaceuticalsMembrane ProteinsGelatinasesAnimalsHumansMiceTissue DistributionPositron Emission Tomography Computed TomographyMaleDose-Response Relationship, DrugSerine EndopeptidasesPC-3 CellsFemaleEndopeptidasesFibroblast Activation Protein Alpha

Stichwörter der Autor:innen

Circulating FAPFAPIGallium-68Improved pharmacokinetics

Substanzen

RadiopharmaceuticalsMembrane ProteinsGelatinasesSerine EndopeptidasesEndopeptidasesFibroblast Activation Protein Alpha

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Inselspital, Bern University Hospital, Bern, Switzerland.
  • Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India.
  • Department of Chemistry-TRIGA site, Johannes Gutenberg-University Mainz, Mainz, Germany.
  • Department of Nuclear Medicine, Inselspital, Bern University Hospital, Bern, Switzerland. eleni.gourni@insel.ch.

ORCID-Profile: Eleni Gourni

Förderung

  • University of Bern

Zitieren

APA

Bilinska, A., Ballal, S., Bal, C., Läppchen, T., Pilatis, E., Menéndez, E., Moon, E. S., Martin, M., Rösch, F., Rominger, A., & Gourni, E. (2025). Improved FAPI-radiopharmaceutical pharmacokinetics from the perspectives of a dose escalation study. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-025-07141-1

Vancouver

Bilinska A, Ballal S, Bal C, Läppchen T, Pilatis E, Menéndez E, et al. Improved FAPI-radiopharmaceutical pharmacokinetics from the perspectives of a dose escalation study. European Journal of Nuclear Medicine and Molecular Imaging. 2025. doi:10.1007/s00259-025-07141-1

BibTeX
@article{Bilinska2025,
  author = {Bilinska, Adrianna and Ballal, Sanjana and Bal, Chandrasekhar and Läppchen, Tilman and Pilatis, Eirinaios and Menéndez, Elena and Moon, Euy Sung and Martin, Marcel and Rösch, Frank and Rominger, Axel and Gourni, Eleni},
  title = {Improved FAPI-radiopharmaceutical pharmacokinetics from the perspectives of a dose escalation study},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2025},
  doi = {10.1007/s00259-025-07141-1}
}
Kostenlos starten →